發(fā)布時間：2018-05-19 23:11

  本文選題：PAX2 + C-MYC�。� 參考：《右江民族醫(yī)學院》2017年碩士論文

【摘要】：目的:探討PAX2與C-MYC在子宮內膜癌中發(fā)生發(fā)展的作用,進一步分析子宮內膜癌中PAX2及C-MYC表達與臨床病理參數(shù)的關系,為子宮內膜癌機制研究和臨床早期診斷提供新的思路。方法:收集2014年10月至2016年10月右江民族醫(yī)學院附屬醫(yī)院和附屬河池醫(yī)院手術切除子宮內膜癌組織60例、不典型增生組織35例、正常子宮內膜組織35例;采用免疫組化(IHC)檢測PAX2及C-MYC在三種不同子宮內膜中蛋白表達情況;從以上標本中留取新鮮子宮內膜癌組織30例、不典型增生組織12例、正常子宮內膜組織15例;應用實時熒光定量聚合酶鏈反應(Quantitative Real-time PCR,Q-PCR)檢測PAX2與C-MYC m RNA在子宮內膜癌、不典型增生內膜及正常子宮內膜組織中表達。所有數(shù)據采用SPSS17軟件進行分析,以P0.05認為具有統(tǒng)計學意義。結果:(1)免疫組化(IHC):PAX2在正常子宮內膜組、不典型子宮內膜組、子宮內膜癌組陽性表達率分別為74.29%,48.57%,43.3%,三組之間陽性表達率差異具有統(tǒng)計學意義(P0.05)。PAX2在正常子宮內膜組陽性率高于不典型增生組(P0.05)和子宮內膜癌組(P0.01);子宮內膜癌組陽性表達率低于不典型增生組,差異無統(tǒng)計學意義(P0.05)。PAX2蛋白表達與子宮內膜癌組織的病理分化程度(P0.05)、肌層浸潤深度相關(P0.05),與淋巴結轉移、臨床分期、年齡、病理分型無關(P0.05)。C-MYC蛋白在正常子宮內膜組、不典型增生組、子宮內膜癌組陽性表達率分別為17.14%,40.0%,66.67%,三組間陽性表達率差異具有統(tǒng)計學意義(P0.05)。C-MYC在子宮內膜癌組中的陽性表達率高于正常內膜組(P0.01)和不典型增生內膜組(P0.05),不典型增生內膜組中陽性率高于正常內膜組(P0.01)。C-MYC蛋白水平表達與子宮內膜癌患者的病理分化(P0.05)、手術-臨床分期(P0.05)密切相關;與肌層浸潤深度、淋巴結轉移、年齡、病理分型無關(P0.05)。(2)實時熒光定量PCR(Q-PCR):PAX2 mRNA在不同子宮內膜組織中表達量總體有差異(P0.01)。PAX2mRNA在子宮內膜癌組中表達水平低于正常子宮內膜對照組(P0.01);不典型增生組PAX2 mRNA低于正常子宮內膜組(P0.01);子宮內膜癌組低于不典型增生內膜組(P0.05)。C-MYC mRNA在不同子宮內膜組織中表達水平總體有差異(P0.001)。C-MYC m RNA在正常子宮內膜組表達水平高于子宮內膜癌組(P0.01)、不典型增生內膜組(P0.01),子宮內膜癌組中的mRNA表達高于不典型增生內膜組(P0.01)。結論:(1)PAX2在不典型增生組織、子宮內膜癌組織中的表達低于正常子宮內膜組織,提示PAX2表達下調可能是子宮內膜不良病變的早期事件。(2)C-MYC在子宮內膜癌組織中表達上調,可能促進了子宮內膜癌的發(fā)生發(fā)展,C-MYC有可能成為子宮內膜癌潛在的診斷和治療靶點。
[Abstract]:Objective: to investigate the role of PAX2 and C-MYC in the occurrence and development of endometrial carcinoma, and to further analyze the relationship between the expression of PAX2 and C-MYC and clinicopathological parameters in endometrial carcinoma, so as to provide a new idea for the study of mechanism and early clinical diagnosis of endometrial carcinoma. Methods: from October 2014 to October 2016, 60 cases of endometrial carcinoma, 35 cases of atypical hyperplasia and 35 cases of normal endometrium were collected from affiliated Hospital and affiliated Hechi Hospital of Youjiang National Medical College. The expression of PAX2 and C-MYC in three kinds of endometrium were detected by immunohistochemistry, 30 cases of fresh endometrial carcinoma, 12 cases of atypical hyperplasia and 15 cases of normal endometrium were collected from above samples. The expression of PAX2 and C-MYC m RNA in endometrial carcinoma, atypical hyperplasia and normal endometrium was detected by real-time quantitative Real-time PCR Q-PCR. All the data were analyzed by SPSS17 software, and P0.05 was considered statistically significant. Results in the normal endometrium group and the atypical endometrium group, the immunohistochemical staining showed that IHC: PAX2 was found in the normal endometrium group and the atypical endometrium group. The positive rate of positive expression in endometrial carcinoma group was 74.29 and 48.57 and 43.3 respectively. The positive expression rate of P0.05U. PAX2 in normal endometrium group was significantly higher than that in atypical hyperplasia group (P0.05) and endometrial carcinoma group (P0.01a). The expression rate was lower than that in atypical hyperplasia group. There was no significant difference between the expression of P0.05, PAX2 protein and the degree of pathological differentiation of endometrial carcinoma. The depth of myometrium invasion was correlated with lymph node metastasis, clinical stage, age and pathological classification. There was no significant difference between P0.05 and C-MYC protein in normal endometrium. Atypical hyperplasia group, The positive expression rates of P0.05, C-MYC in endometrial carcinoma group were significantly higher than those in normal endometrial carcinoma group (P 0.01) and atypical hyperplasia endometrium group (P 0.05%, P 0.05%). The positive rate in endometrial group was higher than that in normal endometrium group. The expression of C-MYC protein was closely related to the pathological differentiation of endometrial carcinoma patients (P0.05, operation-clinical stage, P0.05). Depth of myometrial invasion, lymph node metastasis, age, The expression of real-time quantitative PCR(Q-PCR):PAX2 mRNA in different endometrial tissues was lower than that in normal endometrial carcinoma group (P 0.01) and PAX2 mRNA in atypical hyperplasia group was lower than that in normal endometrium control group (P 0.01), while the expression of P0.01 + PAX2 mRNA in endometrial carcinoma group was lower than that in normal endometrial carcinoma group (P < 0.05), while that in atypical hyperplasia group was lower than that in normal endometrial tissue. The expression of P0. 05 mRNA in endometrial carcinoma group was lower than that in atypical hyperplasia endometrium group. There was a general difference in the expression level of P0. 001. C-MYC m RNA in different endometrial tissues. The expression level of C-MYC m RNA in normal endometrium group was higher than that in endometrial carcinoma group (P0. 01). The expression of mRNA in endometrial carcinoma group was higher than that in atypical hyperplasia group. Conclusion the expression of PAX2 in atypical hyperplasia and endometrial carcinoma is lower than that in normal endometrial tissue, suggesting that the down-regulation of PAX2 expression may be an early event of adverse endometrial lesions. C-MYC may be a potential target for the diagnosis and treatment of endometrial carcinoma.
【學位授予單位】：右江民族醫(yī)學院
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R737.33

【參考文獻】

相關期刊論文 前10條

1 Ferenc Sipos;Gábor Firneisz;Gy?rgyi M?zes;;Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases[J];World Journal of Gastroenterology;2016年35期

2 鄒治銘;郭華雄;;C-myc在腫瘤中作用的研究進展[J];現(xiàn)代醫(yī)學;2016年07期

3 陳晨;郭遂群;;子宮內膜癌組織中DAPK3和c-Myc的表達及其與患者預后的關系[J];南方醫(yī)科大學學報;2016年06期

4 李麗;吳玉斌;徐海生;王長山;;沉默PAX2基因對腎間質纖維化大鼠的影響[J];中國當代兒科雜志;2016年06期

5 宋春麗;呼君瑜;李美艷;田芬;王菊榮;焦茹;劉平;;FHIT、C-myc在宮頸癌中的表達及其與高危型HPV感染的相關性[J];中國腫瘤;2016年05期

6 張盼;寇瑤;李國清;杜柏均;邵金輝;田靜;;PAX6基因突變與先天性無虹膜癥[J];基因組學與應用生物學;2016年03期

7 王亞勤;劉翔;吳晨;唐義虎;吳延虎;;c-Myc基因在人非小細胞肺癌中的表達及基因沉默抑制H1299細胞效果的實驗研究[J];南京醫(yī)科大學學報(自然科學版);2016年02期

8 劉偉;孫志強;謝紅衛(wèi);;基因組織特異性相關研究進展[J];生物化學與生物物理進展;2016年01期

9 袁雪芹;張廷國;荊福祥;李亞楠;張冰;;四硝酸戊赤蘚醇5與配對盒基因在子宮內膜癌及子宮內膜上皮內瘤變中的臨床表達研究[J];中華醫(yī)院感染學雜志;2016年02期

10 Sherri Rennoll;Gregory Yochum;;Regulation of MYC gene expression by aberrant Wnt/β-catenin signaling in colorectal cancer[J];World Journal of Biological Chemistry;2015年04期

相關博士學位論文 前5條

1 張英蘭;子宮內膜癌患者生存預后分析及早期篩查[D];北京協(xié)和醫(yī)學院;2016年

2 陳紅漫;Wnt10a/Wnt10b及其Wnt/β-catenin通路在子宮內膜癌中的作用研究[D];天津醫(yī)科大學;2014年

3 紀曉惠;PAX2、AIB1在乳腺癌組織的表達及其在TAM耐藥機制中作用的研究[D];河北醫(yī)科大學;2014年

4 張昌文;ROCK-c-Myc通路促進腫瘤增殖的分子機制研究[D];天津醫(yī)科大學;2012年

5 朱翠平;PAX2在人發(fā)育腎和病理腎表達的相關研究[D];中南大學;2003年

相關碩士學位論文 前3條

1 張燕;PAX2及AIB1基因在乳腺癌他莫昔芬耐藥機制中的作用的實驗研究[D];河北醫(yī)科大學;2014年

2 賈楠;PAX2在子宮內膜癌中的表達及其DNA甲基化調控[D];復旦大學;2013年

3 鄭瀊冰;原發(fā)性膀胱輸尿管反流Pax2基因啟動子DNA甲基化狀態(tài)研究[D];復旦大學;2012年

，

本文編號：1912106